Key Highlights

  • Basel Medical Group (NASDAQ:BMGL) was down 8.06% in premarket trading on October 9, 2026 on a listed price of USD 3.60, the October 8 close after a 9.76% jump that day.
  • The likeliest catalyst is a best-efforts offering of up to 6,000,000 units at USD 1.33, a prospectus dated October 7, 2026 for up to USD 7.98 million, with delivery expected around October 9.
  • The USD 1.33 unit price is about 63% below the USD 3.60 listed price, and the units would raise the share count from 1,582,111 to as many as 7,582,111, simple arithmetic on published figures.
  • Each unit includes a common Warrant exercisable at 110% of the unit price for five years; Cathay Securities is sole Placement agent with a 6.0% fee of USD 478,800.

What Moved Basel Medical Shares

Basel Medical Group (NASDAQ:BMGL) was indicated down 8.06% in the October 9, 2026 premarket session on the screener, on a listed price of USD 3.60 and premarket Volume of 12,507 shares. The listed price is the October 8 close, when the shares rose about 9.76% from USD 3.28. The catalyst fits a prospectus dated October 7, 2026 for a best-efforts offering of up to 6,000,000 units at USD 1.33 each, for gross proceeds of up to USD 7.98 million, with securities expected to be delivered on or about October 9. The pricing sits far below recent trading, which is why the premarket decline is better read as a repricing than a surprise. Why the shares rose on October 8 is not explained.

The Offering Mechanics

Each unit consists of one ordinary share, or one pre-funded warrant in lieu of a share, and one common warrant. The common warrants are exercisable immediately at 110% of the unit price, or USD 1.463 by simple arithmetic, for five years, and may be exercised on a zero cash basis. Before the offering the company had 1,582,111 shares outstanding, a figure that followed a 1-for-12 reverse split effective June 22, 2026; if all units sold as shares, the count would rise to 7,582,111, an increase of about 379%. Net proceeds of about USD 7.28 million are intended for working capital, acquisitions and general corporate purposes, and Cathay Securities is sole placement agent.

Risks and What to Watch

The offering is best efforts with no minimum, so the amount raised is uncertain, and the combination of heavy share issuance and warrants can pressure the price. Basel Medical Group (NASDAQ:BMGL) also faces a New York securities class action filed in July 2026, a board overhaul announced September 2 and a history of reverse splits and bid price compliance, having regained compliance on July 10. The company, a Singapore provider of orthopedic and related services with 13 practitioners, announced in May 2025 an agreement to buy up to 10,000 Bitcoin with shares, and no completion was confirmed in the material reviewed. Investors should watch the closing announcement and use of proceeds.

Where Things Stand

Basel Medical Group (NASDAQ:BMGL) is down in premarket, and the best-supported cause is a unit offering priced at USD 1.33, far below the USD 3.60 listed price, which would multiply the share count and add warrants. The prospectus is dated October 7 and delivery is expected around October 9. The balance of evidence is that heavy dilution and legal and listing issues outweigh the October 8 jump. The next checkpoints are the closing, the amount actually raised and any further compliance notices.